Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 33

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 33
---
 |

Risks Related to Commercialization of Our Drug Candidates

| ● | Risks                                         
 relating to fail to achieve market acceptance |

<div align='center'>11</div>

Risks Related to Our IP

| ● | Risks                                                            
 relating to being unaware of others’ pending patent applications |

| ● | Risks                                                                        
 relating to unable to protect and enforce our IP rights throughout the world |

| ● | Risks                                                                                       
 relating to lawsuits for protecting our IP or against infringing IP rights of other parties |

| ● | Risks                                                                                                   
 relating to non-compliance with patent protection requirements or obligations in the license agreements |

| ● | Risks                                                                                   
 relating to the terms and scope of our patents not sufficient to protect our candidates |

| ● | Risks                                                                                                         
 relating to unable to obtain or maintain rights of the developing technology through acquisitions or licenses |

Risks Related to Our Reliance on Unrelated Parties

| ● | Risks                                                                                                                                      
 relating to manufacturers fail to provide sufficient quantities of clinical supply on our candidate at acceptable quality levels or prices |

Risks Related to Our Industry, Business and Operation

| ● | Risks                               
 relating to not complying with laws |

| ● | Risks                                           
 relating to difficulties in managing our growth |

| ● | Risks                                                                                                                                
 relating to unable to collaborations, strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements |

| ● | Risks                                                                                        
 relating to our disclosure controls and procedures and internal financial reporting controls |

| ● | Risks                                   
 relating to do business internationally |

| ● | Risks                                                             
 relating to product liability lawsuits arise from clinical trials |

| ● | Risks                                     
 relating to inadequate insurance coverage |

| ● | Risks                                                           
 relating to failure in safeguarding our computer network system |

| ● | Risks                                                                                                                             
 relating to outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease |

<div align='center'>12</div>

Risks Related to Our Corporate Structure

| ● | Risks                                                          
 relating to our Class B shareholders have higher voting rights |

Risks Related to Our Securities

| ● | Risks                                                                                                                                 
 relating to certain existing shareholders have substantial influence over our Company and their interests may not be aligned with the 
 interests of our other shareholders                                                                                                   |

| ● | Risks                                                                             
 relating to conduct substantially all of our operations outside the United States |

| ● | Risks                                                                                                        
 relating to adopt certain home country practices or take